Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This is a phase II, single center, randomized, double-blind, placebo-controlled, study in
patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.